Our present incomplete understanding of the precise mechanisms for the dual tumour suppressor/tumour promoter roles of the TGF-β superfamily ligands represents a major obstacle to targeting these molecules for the treatment of human cancer [20]. This evidence concerns the gene TGFB1 and neoplasm.